Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 10th at 4:00pm ET NEW YORK, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 16^th Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City. Mr. Bentsur's presentation will take place on Monday, February 10^th, at 4:00pm ET. A live audio webcast of Mr. Bentsur's presentation will be accessible within the Investor Relations section of the Company's website at http://www.keryx.com/webcasts-presentations. An archived version of this webcast will be available following the conclusion of the live presentation. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex^TM (ferric citrate coordination complex), an oral, ferric iron-based compound. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis, conducted pursuant to a Special Protocol Assessment ("SPA") agreement with the FDA. Keryx's New Drug Application ("NDA"), submitted to the FDA in 2013, is currently under review and has an assigned Prescription Drug User Fee Act ("PDUFA") goal date of June 7, 2014. Zerenex has also completed a Phase 2 study in the U.S. for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. Top-line results from this Phase 2 study were announced in November 2013. In addition, Keryx's Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd., received marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease on January 17, 2014. Keryx is headquartered in New York City. CONTACT: KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: firstname.lastname@example.org Keryx Logo
Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Press spacebar to pause and continue. Press esc to stop.